Pediatric Endocrinology News

Children with presymptomatic type 1 diabetes progressed more quickly to type 1 diabetes after having COVID-19, according to a research letter published in JAMA.

Circulating levels of some microRNA species may predict response to diabetes treatment and changes in beta-cell function among children and adolescents with type 2 diabetes, according to findings from the TODAY study.

Lack of available health care providers, health insurance exclusions and a lengthy assessment process are among barriers transgender people face when seeking gender-affirming hormone therapy, according to study findings.

ORLANDO — Continuous glucose monitoring metrics can predict imminent stage 3 type 1 diabetes for people who are islet autoantibody positive, according to a speaker at the American Diabetes Association Scientific Sessions.

ORLANDO — Health care inequities led to some children and adolescents starting continuous glucose monitoring more than 6 months after a type 1 diabetes diagnosis, according to data presented here.

Setmelanotide reduced BMI by at least 5% at 16 weeks among 89% of children and adults with hypothalamic obesity, according to findings from a phase 2 trial published in The Lancet Diabetes & Endocrinology.

The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.

BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.

An oral medication that stimulates the growth hormone secretagogue receptor 1a induced height velocity increases similar to those seen with recombinant human GH for children with pediatric GH deficiency, according to trial data.

BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.